Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Journal of Colorectal Disease
Erschienen in: International Journal of Colorectal Disease 11/2019

22.10.2019 | Original Article

Long-term results achieved by guideline-based stage-dependent management of anal cancer in a non-HIV population

verfasst von: Bernhard Fankhaenel, Joerg Zimmer, Dorothea Bleyl, Eric Puffer, Andreas Schreiber, Thomas Kittner, Helmut Witzigmann, Sigmar Stelzner

Erschienen in: International Journal of Colorectal Disease | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Therapy of anal cancer follows national and international guidelines that are mainly derived from randomized trials. This study aimed to analyze long-term results of stage-dependent treatment of anal cancer in a non-selected patient cohort.

Patients and method

All consecutive patients treated for anal cancer between 2000 and 2015 were retrieved from a prospective database. Risk-dependent screening for human immunodeficiency virus showed no infection. Main outcome measure was overall survival with respect to tumor site and treatment. Secondary endpoints were cause-specific survival, stoma free survival, and the rate of salvage operations.

Results

In total, 106 patients were treated for anal cancer. Of those, 69 (65.1%) suffered from anal canal cancer and 37 (34.9%) from anal margin cancer. Three patients with synchronous distant metastases were excluded from analysis. The majority of patients (n = 79, 76.7%) were treated by chemoradiotherapy in curative intention. Twenty-two patients underwent local surgery. Five-year overall survival was 73.1% and cause-specific survival at 5 years was 87.4%. Overall, 14 patients (13.6%) needed salvage surgery. Their 5-year cause-specific survival was 57.7%. A permanent ostomy was avoided in 77.7%.

Conclusions

Treatment of anal cancer results in low rates of salvage surgery and permanent ostomies, when therapy was determined by a multidisciplinary team following national and international guidelines.
Literatur
1.
Alfa-Wali M, Dalla Pria A, Nelson M, Tekkis P, Bower M (2016) Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol 42:813–816CrossRef
2.
Garrett K, Kalady MF (2010) Anal neoplasms. Surg Clin N Am 90:147–161CrossRef
3.
Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D (2014) Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii 10–iii 20CrossRef
4.
Gimenez F, Costa-e-Silva IT, Daumas A, Araujo J, Medeiros SG, Ferreira L (2011) The value of high-resolution anoscopy in the diagnosis of anal cancer precursor lesions in HIV-positive patients. Arq Gastroenterol 48:136–145CrossRef
5.
Wilkinson JR, Morris EJ, Downing A, Aravani A, Thomas JD, Sebag-Montefiore D (2014) The rising incidence of anal cancer in England 1990-2010: a population-based study. Color Dis 16:O234–O239CrossRef
6.
Salati SA, Al Kadi A (2012) Anal cancer—a review. Int J Health Sci (Qassim) 6:206–230CrossRef
7.
Nigro ND, Vaitkevicius VK, Considine B Jr (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17:354–356CrossRef
8.
Glynne-Jones R, Saleem W, Harrison M, Mawdsley S, Hall M (2016) Background and current treatment of squamous cell carcinoma of the anus. Oncol Ther 4:135–172CrossRef
9.
Aggarwal A, Duke S, Glynne-Jones R (2013) Anal cancer: are we making progress? Curr Oncol Rep 15:170–181CrossRef
10.
National Comprehensive Cancer Network NCCN (2016) Clinical practice guidelines in oncology, anal carcinoma. Version I.2017. http://​www.​nccn.​org. Accessed 25 May 2018
11.
Schmitt-Reisser B (2004) In: Krebsgesellschaft D (ed) Kurzgefasste interdisziplinäre Leitlinien 2004. Diagnostik und Therapie maligner Erkrankungen, 4th edn. Zuckschwerdt, München, pp 190–198
12.
13.
Brierley JD, Gospodarowicz MK, Wittekind C (2016) Anal canal and perianal skin. In: Brierley JD, Gospodarowicz MK, Wittekind C (eds) TNM classification of malignant tumors, 8th edn. Wiley-Blackwell, Chichester, pp 77–80
14.
Geltzeiler CB, Nabavizadeh N, Kim J, Kim CL, Billingsley KG, Thomas CR, Herzig DO, Tsikitis VL (2014) Chemoradiotherapy with a radiation boost for anal cancer decreases the risk for salvage abdominoperineal resection: analysis from the national cancer data base. Ann Surg Oncol 21:3616–3620CrossRef
15.
Alamri Y, Buchwald P, Dixon L, Dobbs B, Eglinton T, McCormick J, Wakeman C, Frizelle FA (2016) Salvage surgery in patients with recurrent or residual squamous cell carcinoma of the anus. Eur J Surg Oncol 42:1687–1692CrossRef
16.
Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM, Jitlal M (2013) Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer 119:748–755CrossRef
17.
James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 14:516–524CrossRef
18.
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344–4351CrossRef
19.
Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30:1941–1948CrossRef
20.
Fleshner PR, Chalasani S, Chang GJ, Levien DH, Hyman NH, Buie WD, Standards Practice Task Force, American Society of Colon and Rectal Surgeons (2008) Practice parameters for anal squamous neoplasms. Dis Colon Rectum 51:2–9CrossRef
21.
Steele SR, Varma MG, Melton GB, Ross HM, Rafferty JF, Buie WD, Standards Practice Task Force of the American Society of Colon and Rectal Surgeons (2012) Practice parameters for anal squamous neoplasms. Dis Colon Rectum 55:735–749CrossRef
22.
Glynne-Jones R, Northover JMA, Cervantes A (2010) Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v87–v92CrossRef
23.
Madlung A (2019) Radiotherapy of anal and rectal cancer. Squamous cell anal carcinoma from a radiologic perspective. Coloproctology 41:255–261CrossRef
24.
Williams M, Swampillai A, Osborne M, Mawdsley S, Hughes R, Harrison M, Harvey R, Glynne-Jones R (2013) Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. Cancer 119:2391–2398CrossRef
25.
Nelson VM, Benson AB 3rd (2017) Epidemiology of anal canal cancer. Surg Oncol Clin N Am 26:9–15CrossRef
26.
Amirian ES, Fickey PA Jr, Scheurer ME, Chiao EY (2013) Anal cancer incidence and survival: comparing the greater San-Francisco bay area to other SEER cancer registries. PLoS One 8:e58919CrossRef
27.
28.
29.
Kim E, Kim JS, Choi M, Thomas CR Jr (2016) Conditional survival in anal carcinoma using the National Population-Based Survey of epidemiology and end results database (1988-2012). Dis Colon Rectum 59:291–298CrossRef
30.
Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A (2009) Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 52:624–631CrossRef
31.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299:1914–1921CrossRef
32.
Chakravarthy AB, Catalano PJ, Martenson JA, Mondschein JK, Wagner H, Mansour EG, Talamonti MS, Benson AB 3rd (2011) Long-term follow-up of a phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). Int J Radiat Oncol Biol Phys 81:e607–e613CrossRef
33.
Delhorme JB, Antoni D, Mak KS, Severac F, Freel KC, Schumacher C, Rohr S, Brigand C, Noel G (2016) Treatment that follows guidelines closely dramatically improves overall survival of patients with anal canal and margin cancers. Crit Rev Oncol Hematol 101:131–138CrossRef
34.
Harris DA, Williamson J, Davies M, Evans MD, Drew P, Beynon J (2013) Outcome of salvage surgery for anal squamous cell carcinoma. Color Dis 15:968–973CrossRef
35.
Hardt J, Mai S, Weiß C, Kienle P, Magdeburg J (2016) Abdominoperineal resection and perineal wound healing in recurrent, persistent, or primary anal carcinoma. Int J Color Dis 31:1197–1203CrossRef
36.
Mariani P, Ghanneme A, De la Rochefordière A, Girodet J, Falcou MC, Salmon RJ (2008) Abdominoperineal resection for anal cancer. Dis Colon Rectum 51:1495–1501CrossRef
37.
Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL (2009) HIV and anal cancer outcomes: a single institution’s experience. Dis Colon Rectum 52:891–897CrossRef
38.
Hannes S, Reinisch A, Bechstein WO, Habbe N (2016) Salvage abdominoperineal excisions in recurrent anal cancer--impact of different reconstruction techniques on outcome, morbidity, and complication rates. Int J Color Dis 31:653–659CrossRef
39.
Guerra GR, Kong JC, Bernardi MP, Ramsay RG, Phillips WA, Warrier SK, Lynch AC, Ngan SY, Heriot AG (2018) Salvage surgery for locoregional failure in anal squamous cell carcinoma. Dis Colon Rectum 61:179–186CrossRef
40.
Chai CY, Tran Cao HS, Awad S, Massarweh NN (2018) Management of stage I squamous cell carcinoma of the anal canal. JAMA 153:209–215
41.
Chang GJ, Welton ML (2004) Human papillomavirus, condylomata acuminata, and anal neoplasia. Clin Colon Rectal Surg 17:221–230CrossRef
42.
Mennini FS, Bonanni P, Bianic F, de Waure C, Baio G, Plazzotta G, Uhart M, Rinaldi A, Largeron N (2017) Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc 15:11CrossRef
43.
Villa LL, Costa RL, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459–1466CrossRef
Metadaten
Titel
Long-term results achieved by guideline-based stage-dependent management of anal cancer in a non-HIV population
verfasst von
Bernhard Fankhaenel
Joerg Zimmer
Dorothea Bleyl
Eric Puffer
Andreas Schreiber
Thomas Kittner
Helmut Witzigmann
Sigmar Stelzner
Publikationsdatum
22.10.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 11/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-019-03396-x

Weitere Artikel der Ausgabe 11/2019

International Journal of Colorectal Disease 11/2019 Zur Ausgabe

Original Article

Epidemiology of and prognostic factors for appendiceal carcinomas: a retrospective, population-based study

Original Article

MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer

Case Report

Feasibility and safety of laparoscopic colorectal surgeries for patients with left ventricular assist device

Original Article

Time-saving polyp detection in colon capsule endoscopy: evaluation of a novel software algorithm

Original Article

Clinical, oncological, and functional outcomes of Da Vinci (Xi)–assisted versus conventional laparoscopic resection for rectal cancer: a prospective, controlled cohort study of 51 consecutive cases

Original Article

Clinicopathological characteristics and frequency of multiple rectal neuroendocrine tumors: a single-center retrospective study

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.